Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide.

We have previously shown that hemizygous transgenic mice expressing human islet amyloid polypeptide (hIAPP) in pancreatic beta-cells have no diabetic phenotype, whereas in the homozygous state, they developed severe, early-onset hyperglycemia associated with impaired insulin secretion and beta-cell death. We investigated the possibility that when the hemizygous mice are crossed onto an obese, insulin-resistant strain such as agouti viable yellow (A(vy)/a), they would exhibit a phenotype more akin to human type 2 diabetes. The hIAPP-expressing A(vy) males (TG-Y) displayed fasting hyperglycemia at 90 days of age and by 1 year progressed to severe hyperglycemia relative to their nontransgenic counterparts. Plasma insulin concentrations and pancreatic insulin content dropped 10- to 20-fold, suggesting severe impairment of beta-cell function. Histopathological findings revealed beta-cell degeneration and loss consistent with the drop in the plasma insulin concentration. In addition, large deposits of IAPP amyloid were present in TG-Y islets. We conclude that in transgenic mice expressing hIAPP, insulin resistance can induce overt, slow-onset diabetes associated with islet amyloid and decreased beta-cell mass.

[1]  R. Silvestre,et al.  Effect of (8–32) salmon calcitonin, an amylin antagonist, on insulin, glucagon and somatostatin release: study in the perfused pancreas of the rat , 1996, British journal of pharmacology.

[2]  R. DeFronzo,et al.  Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes. , 1979, The Journal of clinical investigation.

[3]  N. Eberhardt,et al.  Islet Amyloid Polypeptide (IAPP) and Insulin Secretion , 1994 .

[4]  D. W. Hayden,et al.  Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. , 1987, The American journal of pathology.

[5]  J. Sturis,et al.  Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. , 1996, The New England journal of medicine.

[6]  B. Hellman,et al.  The Islets of Langerhans in yellow obese mice. , 1963, Metabolism: clinical and experimental.

[7]  D. Longnecker,et al.  The relation of islet amyloid to the clinical type of diabetes. , 1981, Human pathology.

[8]  D. Steiner,et al.  Human islet amyloid polypeptide transgenic mice as a model of non‐insulin‐dependent diabetes mellitus (NIDDM) , 1993, FEBS letters.

[9]  B. Chesebro,et al.  Prion protein and the transmissible spongiform encephalopathies. , 1997, Trends in cell biology.

[10]  P. Bennett,et al.  The natural history of impaired glucose tolerance in the Pima Indians. , 1988, The New England journal of medicine.

[11]  J. Rothbard,et al.  Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[12]  W. Soeller,et al.  Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Fajans Ss,et al.  Influence of adrenal cortical steroids on carbohydrate metabolism in man. , 1956 .